Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: When statistics make a difference

British Journal of Dermatology

Volumn 161, Issue 1, 2009, Pages 215-216

  Mangano, A ^a   Albertin, A ^b   La Colla, L ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Nodular basal cell carcinoma; Power; Sample size; Statistics

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; AMINOLEVULINIC ACID; IRON CHELATING AGENT;

BASAL CELL CARCINOMA; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; HUMAN; LETTER; METHODOLOGY; PAIN ASSESSMENT; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME; TUMOR VOLUME;

CARCINOMA, BASAL CELL; HUMANS; IRON CHELATING AGENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PYRIDONES; SAMPLE SIZE; SKIN NEOPLASMS;

EID: 67649998775     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09232.x     Document Type: Letter

References (1)

1. Campbell SM, Morton CA, Alyahya R et al. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 2008 159 : 387 93.